Product image of Neoflubin (Fludarabine Phosphate) supplied by GNH India

Neoflubin

Active Ingredient:
Fludarabine Phosphate
Origin:
EU

Neoflubin (Fludarabine Phosphate)

Fludarabine phosphate, the active ingredient in Neoflubin, is an antimetabolite (purine analog) presented as a sterile intravenous solution for IV use. It is employed in chemotherapy regimens to treat certain hematologic malignancies, particularly chronic lymphocytic leukemia and low‑grade non‑Hodgkin lymphoma.

GNH India supplies Neoflubin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across regions. We adhere to EU GMP standards and provide reliable cold‑chain logistics where required.

Manufacturer / TM Owner

Ebewe Pharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Fludarabine phosphate is used in chemotherapy protocols targeting lymphoid malignancies and as part of conditioning regimens for stem cell transplantation.

  • Chronic lymphocytic leukemia: reduces malignant lymphocyte count and induces remission.
  • Low‑grade non‑Hodgkin lymphoma: achieves disease control and prolongs survival.
  • Conditioning for hematopoietic stem cell transplantation: facilitates engraftment by depleting host immune cells.

How It Works

  • Fludarabine phosphate is a purine analog that is intracellularly phosphorylated to its active triphosphate form. The triphosphate competitively inhibits DNA polymerase α, ribonucleotide reductase, and DNA primase, leading to impaired DNA synthesis and repair, causing chain termination and apoptosis of rapidly dividing lymphoid cells. The drug also interferes with RNA synthesis and can affect both dividing and resting lymphocytes, contributing to its immunosuppressive activity.

Side Effects

Fludarabine phosphate may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Myelosuppression: decreased white blood cells, red cells and platelets.
  • Nausea and vomiting: gastrointestinal upset.
  • Fatigue: persistent tiredness.
  • Diarrhea: loose stools that may be watery.

Serious or Rare Side Effects

  • Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia.
  • Autoimmune hemolytic anemia: immune‑mediated destruction of red blood cells.
  • Pulmonary toxicity: interstitial pneumonitis or acute respiratory distress.
  • Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Precautions & Warnings

When using fludarabine phosphate, careful monitoring and specific precautions are essential.

  • Monitor blood counts: regular CBC to detect myelosuppression.
  • Assess renal function: adjust use in renal impairment.
  • Screen for infections: evaluate for active viral, bacterial, or fungal infections before therapy.
  • Avoid use in pregnancy: risk to the fetus is unknown; contraindicated unless essential.
  • Use protective isolation: reduce exposure to opportunistic pathogens during treatment.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Fludarabine phosphate can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

  • Concurrent use with other myelosuppressive agents: may cause severe bone marrow suppression.
  • Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Antiviral agents such as ganciclovir: may increase toxicity.
  • CYP450 substrates: fludarabine may alter metabolism of certain drugs.
  • Allopurinol: may increase risk of hematologic toxicity.

Frequently Asked Questions

Neoflubin contains fludarabine phosphate, an antimetabolite chemotherapy used primarily to treat chronic lymphocytic leukemia, low‑grade non‑Hodgkin lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.

Fludarabine phosphate is converted inside cells to an active triphosphate that blocks DNA polymerase, ribonucleotide reductase, and DNA primase, halting DNA synthesis and triggering apoptosis of rapidly dividing lymphoid cells, while also suppressing RNA synthesis.

The dosage of Neoflubin is individualized by the prescribing oncologist or hematologist based on the specific indication, patient weight, renal function, and treatment protocol. Only a qualified healthcare professional should determine the appropriate regimen.

Safety of fludarabine phosphate in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus, and breastfeeding is usually discontinued during treatment.

To request Neoflubin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and any required import documentation.

Compared with other purine analogs, fludarabine phosphate offers potent activity against indolent lymphoid cancers and is often chosen for its ability to achieve deep remissions. However, its immunosuppressive profile may be greater than some alternatives, requiring careful infection monitoring.

Neoflubin should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Use aseptic technique for preparation and administer promptly after reconstitution according to institutional protocols.

Neoflubin is supplied as a sterile intravenous solution and is administered by slow IV infusion under the supervision of qualified medical personnel, typically in a clinical or hospital setting.

The most serious risks include profound myelosuppression leading to severe infections, autoimmune hemolytic anemia, pulmonary toxicity, and tumor lysis syndrome. Patients should be monitored closely for signs of infection, respiratory distress, and hematologic abnormalities.

Neoflubin is contraindicated in patients with active uncontrolled infections, known hypersensitivity to fludarabine or any excipients, and should be used with extreme caution or avoided in pregnant women, breastfeeding mothers, and individuals with severe renal impairment unless dose adjustments are made.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fludarabine Phosphate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT